Peptide Based Cardiovascular Therapeutics Market will Touch a Value of Nearly US$ 1,960 Mn

Cardiovascular disease is the leading cause of mortality and morbidity all over the world. In the past, the development of peptides as therapeutic agents had been avoided by pharmaceutical industry due to their low stability, rate of degradation and poor delivery. However, in recent times, resurgence has taken place in the field of peptides as therapeutics. Economic factors such as increasing healthcare expenditure and increasing FDI in emerging economies are expected to drive the market of peptide based cardiovascular therapeutics.

Request for the Report Summary: https://www.factmr.com/report/191/peptide-based-cardiovascular-therapeutics-market

Additionally, increasing prevalence of cardiovascular disorders, emergence of prominent pharmaceutical and biotech companies and strong R&D in the development of new peptides are fuelling the market growth. However, various factors such as increasing costs of commercialization, rapid metabolism of peptide drugs and regulatory conditions are expected to hamper market growth.

Therapeutic peptides are used in the treatment of cardiovascular disorders that are a leading cause of mortality and morbidity throughout the world. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=191

The market in North America is set to dominate the global peptide based cardiovascular therapeutics market in terms of value and this trend is projected to sustain itself throughout the assessment period. North America peptide based cardiovascular therapeutics market is the most attractive market, growing at a robust CAGR over the assessment period.

As per the forecast of Fact.MR, the bivalirudin segment is expected to reach a value of nearly US$ 1,360 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Bivalirudin segment is expected to account for more than two-third of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 960 Mn in the year 2022. This represents a CAGR of 8.9% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Request for the Report Customization: https://www.factmr.com/connectus/sample?flag=RC&rep_id=191

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.